True Wealth Design’s Inozyme Pharma INZY Stock Holding History

True Wealth Design’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-67	Closed	-$61	–	2696
2025 Q1	$61	Buy	+67	New	+$93	﹤0.01%	2337

Other funds holding INZY

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

True Wealth Design's INZY Position: Q2 2025 in Review

True Wealth Design sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 67 shares — an estimated $61 sold.

True Wealth Design first reported a position in INZY in Q1 2025 and held it in 1 quarter. The position peaked at $61 in Q1 2025. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

True Wealth Design reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 67 Inozyme Pharma shares in Q2 2025, an estimated $61.
True Wealth Design first reported a position in Inozyme Pharma in Q1 2025 and held it in 1 quarter.
True Wealth Design's Inozyme Pharma position peaked at $61 in Q1 2025.
86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.